News | April 19, 2025
Aptar commences clinical study to accelerate FDA approval of SmartTrack
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
The plant will have installed production capacity of 3,120 MT/month
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The company does not expect this development to have any material impact on the current business operations
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Subscribe To Our Newsletter & Stay Updated
